LONDON, GREATER LONDON, UNITED KINGDOM, July 2, 2025 /EINPresswire.com/ -- The global hypoparathyroidism market sector has observed substantial growth trajectory in recent years, driven by key factors ...

A report published by The Business Research Company reveals that the market size, which stood at $ 13.90 billion in 2024, is poised to grow to $16.52 billion in 2025, reflecting a compound annual ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck has announced plans to build a biologics manufacturing facility in Wilmington, Delaware. The company, which develops and produces medicines and vaccines, has invested $1 billion in the project, ...

Merck & Co. has become a standout player in the Dow thanks to its steady revenue streams and hedge fund popularity. It ranks 17th among Dow stocks based on hedge fund holdings and short interest ...

Merck recently broke ground at a $1 billion production facility in Wilmington, Delaware. The nearly half-million square feet plant is the future home of Keytruda production.

Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center of excellence” in Wilmington, writes John George and Paul Schwedelson for ...

Merck Wilmington Biotech, expected to be operational by 2028, is a new 470,000-square-foot production facility located on the Chestnut Run Innovation and Science Park in Delaware, a sprawling 164 ...

Merck announced that construction has begun on a new $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Del. According to the company, the new site will create 500 full-time ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its blockbuster cancer drug Keytruda. The facility aims to reduce dependency on ...

Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center of excellence” in Wilmington, writes… ...

U.S. biopharmaceutical giant Merck announced the start of construction for a $1-billion, 470,000-sq-ft biologics center of excellence in Wilmington, Del.